Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas, Adil Daud, John M. Kirkwood et al.|The Lancet Oncology|2015

Cited by 1.6k